RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+1.96%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.51B
AUM Growth
-$1.16B
(-13%)
Cap. Flow
+$76.9M
Cap. Flow
% of AUM
1.02%
Top 10 Holdings %
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$160M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Arcellx
ACLX
|
$71.8M |
| 4 |
Janux Therapeutics
JANX
|
$64.2M |
| 5 |
Ascendis Pharma
ASND
|
$55.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$230M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$151M |
| 3 |
Evolent Health
EVH
|
$55.5M |
| 4 |
CG Oncology
CGON
|
$52.7M |
| 5 |
Recursion Pharmaceuticals
RXRX
|
$51.8M |
Sector Composition
| 1 | Healthcare | 98.36% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Zura Bio
ZURA
$132M
| $8.04M | 0.11% |
3,217,503
| – | – |
|
|
PCSC
77
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.64M | 0.1% |
750,000
| – | – |
|
|
BIOA
78
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $7.59M | 0.1% |
1,310,589
-900,000
| -41% | -$5.21M |
|
79
Adicet Bio
ACET
$60.8M
| $7.25M | 0.1% |
7,541,000
| – | – |
|
80
Avalo Therapeutics
AVTX
$139M
| $7.18M | 0.1% |
967,000
| – | – |
|
|
BOLD
81
Boundless Bio
BOLD
$25.7M
| $6.32M | 0.08% |
2,180,631
| – | – |
|
82
Enanta Pharmaceuticals
ENTA
$189M
| $5.97M | 0.08% |
+1,038,000
| New | +$5.97M |
|
83
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $4.75M | 0.06% |
333,333
| – | – |
|
84
Surrozen
SRZN
$107M
| $4.06M | 0.05% |
282,580
| – | – |
|
85
Lexeo Therapeutics
LXEO
$266M
| $3.6M | 0.05% |
546,554
| – | – |
|
|
ALLK
86
DELISTED
Allakos
ALLK
| $1.37M | 0.02% |
+1,129,931
| New | +$1.37M |
|
87
Scholar Rock
SRRK
$3.3B
| $761K | 0.01% |
+17,616
| New | +$761K |
|
|
RGLS
88
DELISTED
Regulus Therapeutics
RGLS
| $532K | 0.01% |
336,843
-429,991
| -56% | -$679K |
|
89
Scilex Holding
SCLX
$131M
| $442K | 0.01% |
29,606
+22,144
| +297% | +$330K |
|
90
Alto Neuroscience
ANRO
$97.7M
| – | – |
-2,075,154
| Closed | -$23.7M |
|
91
AN2 Therapeutics
ANTX
$35.3M
| – | – |
-1,999,997
| Closed | -$2.14M |
|
|
92
Biogen
BIIB
$20.5B
| – | – |
-1,184,456
| Closed | -$230M |
|
|
93
CG Oncology
CGON
$2.19B
| – | – |
-1,397,433
| Closed | -$52.7M |
|
94
CervoMed
CRVO
$93M
| – | – |
-817,120
| Closed | -$11.9M |
|
95
Nuvalent
NUVL
$5.74B
| – | – |
-176,281
| Closed | -$18M |
|
96
Tenaya Therapeutics
TNYA
$192M
| – | – |
-6,982,587
| Closed | -$13.5M |
|
97
Metagenomi
MGX
$67.2M
| – | – |
-1,305,239
| Closed | -$2.83M |
|
|
ADGM
98
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.1M
| – | – |
-1,333,926
| Closed | -$3.44M |
|